Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study-Reference-Cited by-同舟云学术

Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study

Published:2015-03 Issue: Volume:48 Page:328-336
ISSN:0928-4931
Container-title:Materials Science and Engineering: C
language:en
Short-container-title:Materials Science and Engineering: C

Author:

Esposito Elisabetta,Ravani Laura,Drechsler Markus,Mariani Paolo,Contado Catia,Ruokolainen Janne,Ratano Patrizia,Campolongo Patrizia,Trezza Viviana,Nastruzzi Claudio,Cortesi Rita

Funder

FIRB FUTURO IN RICERCA 2010

Publisher

Elsevier BV

Subject

Biomaterials,Bioengineering,Mechanics of Materials

Reference57 articles.

1. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors;Pertwee;Life Sci.,2005

2. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis;Janero;Expert Opin. Emerg. Drugs,2009

3. The endocannabinoid system as an emerging target of pharmacotherapy;Pacher;Pharmacol. Rev.,2006

4. Cannabinoid receptors as therapeutic targets;Mackie;Annu. Rev. Pharmacol. Toxicol.,2006

5. The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD);Trezza;Front. Behav. Neurosci.,2013

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nose to brain delivery of escitalopram-loaded nano-structured lipid carriers thermosensitive gel: Formulation, physiochemical, pharmacokinetic and pharmacodynamics evaluation;Journal of Drug Delivery Science and Technology;2024-08

2. Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects;Current Pharmaceutical Biotechnology;2024-01

3. CB65 and novel CB65 liposomal system suppress MG63 and Saos-2 osteosarcoma cell growth in vitro;Journal of Liposome Research;2023-09-23

4. Design and development of donepezil hydrochloride loaded nanostructured lipid carriers for efficient management of Alzheimer’s disease;Drug Development and Industrial Pharmacy;2023-09-02

5. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes;Journal of Controlled Release;2023-01